PPARG and Alzheimer disease: Moreover, combining PPARγ agonists with other therapies, such as anti- Aβ treatments or glucagon-like peptide-1 (GLP-1) receptor agonists, is being explored to improve both metabolic function and cognitive outcomes in AD patients.